FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071283345> ?p ?o ?g. }

• W2071283345 endingPage "1572" @default.
• W2071283345 startingPage "1567" @default.
• W2071283345 abstract "ObjectivePreexisting serum antibodies to heparin/platelet factor 4 complexes may predispose adult cardiac surgical patients to increased perioperative morbidity and mortality. We sought to determine the association between preoperative serum antibodies directed against platelet factor 4/heparin complexes and major complications (in-hospital death or length of stay >10 days) in adult cardiac surgical patients.MethodsIn a prospective observational study of 466 patients undergoing elective coronary artery bypass grafting, valvular heart surgery, or both, preoperative serum was assayed for anti–platelet factor 4/heparin antibody by using a commercially available enzyme-linked immunosorbent assay (Asserachrom HPIA). Known preoperative risk factors were assessed, and patients were assigned a risk score by using the validated method of Parsonnet and colleagues.ResultsMajor complications (death or postoperative hospitalization >10 days) occurred in 108 patients (23%). Overall, 59 (13%) patients had a positive preoperative anti–platelet factor 4/heparin antibody screen (upper limit of normal is 0.5 optical density units). A positive assay result independently predicted an increased risk of major complications (P = .0284; odds ratio, 1.98; 95% confidence interval, 1.06-3.62) over and above the effect of the Parsonnet risk score (P < .001; odds ratio, 1.07; 95% confidence interval, 1.05-1.10). The level of preoperative anti–platelet factor 4/heparin antibody was also significantly associated with major complications (P = .036; odds ratio, 1.31; 95% confidence interval, 1.02-1.68) independently of the Parsonnet risk score. No association (P > .75) existed between the Parsonnet risk score and preoperative anti–platelet factor 4/heparin antibody level.ConclusionsSerum antibodies directed against platelet factor 4/heparin complexes are prevalent in the adult patient population undergoing cardiac surgery. The presence of these antibodies before surgery is an independent predictor for death or prolonged hospitalization after adult cardiac surgery. Preexisting serum antibodies to heparin/platelet factor 4 complexes may predispose adult cardiac surgical patients to increased perioperative morbidity and mortality. We sought to determine the association between preoperative serum antibodies directed against platelet factor 4/heparin complexes and major complications (in-hospital death or length of stay >10 days) in adult cardiac surgical patients. In a prospective observational study of 466 patients undergoing elective coronary artery bypass grafting, valvular heart surgery, or both, preoperative serum was assayed for anti–platelet factor 4/heparin antibody by using a commercially available enzyme-linked immunosorbent assay (Asserachrom HPIA). Known preoperative risk factors were assessed, and patients were assigned a risk score by using the validated method of Parsonnet and colleagues. Major complications (death or postoperative hospitalization >10 days) occurred in 108 patients (23%). Overall, 59 (13%) patients had a positive preoperative anti–platelet factor 4/heparin antibody screen (upper limit of normal is 0.5 optical density units). A positive assay result independently predicted an increased risk of major complications (P = .0284; odds ratio, 1.98; 95% confidence interval, 1.06-3.62) over and above the effect of the Parsonnet risk score (P < .001; odds ratio, 1.07; 95% confidence interval, 1.05-1.10). The level of preoperative anti–platelet factor 4/heparin antibody was also significantly associated with major complications (P = .036; odds ratio, 1.31; 95% confidence interval, 1.02-1.68) independently of the Parsonnet risk score. No association (P > .75) existed between the Parsonnet risk score and preoperative anti–platelet factor 4/heparin antibody level. Serum antibodies directed against platelet factor 4/heparin complexes are prevalent in the adult patient population undergoing cardiac surgery. The presence of these antibodies before surgery is an independent predictor for death or prolonged hospitalization after adult cardiac surgery." @default.
• W2071283345 created "2016-06-24" @default.
• W2071283345 creator A5024150275 @default.
• W2071283345 creator A5033680488 @default.
• W2071283345 creator A5055415791 @default.
• W2071283345 creator A5069172766 @default.
• W2071283345 creator A5085899378 @default.
• W2071283345 creator A5086401839 @default.
• W2071283345 creator A5088652167 @default.
• W2071283345 date "2005-12-01" @default.
• W2071283345 modified "2023-09-23" @default.
• W2071283345 title "Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery" @default.
• W2071283345 cites W1892579436 @default.
• W2071283345 cites W1981406415 @default.
• W2071283345 cites W1990893901 @default.
• W2071283345 cites W2009549527 @default.
• W2071283345 cites W2023548160 @default.
• W2071283345 cites W2027896336 @default.
• W2071283345 cites W2051871997 @default.
• W2071283345 cites W2053593414 @default.
• W2071283345 cites W2070650376 @default.
• W2071283345 cites W2083425460 @default.
• W2071283345 cites W2084688676 @default.
• W2071283345 cites W2089914183 @default.
• W2071283345 cites W2135344285 @default.
• W2071283345 cites W2135780868 @default.
• W2071283345 cites W2162688941 @default.
• W2071283345 cites W2316071283 @default.
• W2071283345 cites W2322121630 @default.
• W2071283345 cites W2470401733 @default.
• W2071283345 cites W3023804638 @default.
• W2071283345 doi "https://doi.org/10.1016/j.jtcvs.2005.07.052" @default.
• W2071283345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16308000" @default.
• W2071283345 hasPublicationYear "2005" @default.
• W2071283345 type Work @default.
• W2071283345 sameAs 2071283345 @default.
• W2071283345 citedByCount "74" @default.
• W2071283345 countsByYear W20712833452012 @default.
• W2071283345 countsByYear W20712833452013 @default.
• W2071283345 countsByYear W20712833452014 @default.
• W2071283345 countsByYear W20712833452015 @default.
• W2071283345 countsByYear W20712833452016 @default.
• W2071283345 countsByYear W20712833452017 @default.
• W2071283345 countsByYear W20712833452018 @default.
• W2071283345 countsByYear W20712833452020 @default.
• W2071283345 countsByYear W20712833452021 @default.
• W2071283345 countsByYear W20712833452022 @default.
• W2071283345 countsByYear W20712833452023 @default.
• W2071283345 crossrefType "journal-article" @default.
• W2071283345 hasAuthorship W2071283345A5024150275 @default.
• W2071283345 hasAuthorship W2071283345A5033680488 @default.
• W2071283345 hasAuthorship W2071283345A5055415791 @default.
• W2071283345 hasAuthorship W2071283345A5069172766 @default.
• W2071283345 hasAuthorship W2071283345A5085899378 @default.
• W2071283345 hasAuthorship W2071283345A5086401839 @default.
• W2071283345 hasAuthorship W2071283345A5088652167 @default.
• W2071283345 hasBestOaLocation W20712833451 @default.
• W2071283345 hasConcept C126322002 @default.
• W2071283345 hasConcept C141071460 @default.
• W2071283345 hasConcept C156957248 @default.
• W2071283345 hasConcept C159973064 @default.
• W2071283345 hasConcept C164705383 @default.
• W2071283345 hasConcept C2777557582 @default.
• W2071283345 hasConcept C2777722626 @default.
• W2071283345 hasConcept C31174226 @default.
• W2071283345 hasConcept C42219234 @default.
• W2071283345 hasConcept C44249647 @default.
• W2071283345 hasConcept C50440223 @default.
• W2071283345 hasConcept C71924100 @default.
• W2071283345 hasConceptScore W2071283345C126322002 @default.
• W2071283345 hasConceptScore W2071283345C141071460 @default.
• W2071283345 hasConceptScore W2071283345C156957248 @default.
• W2071283345 hasConceptScore W2071283345C159973064 @default.
• W2071283345 hasConceptScore W2071283345C164705383 @default.
• W2071283345 hasConceptScore W2071283345C2777557582 @default.
• W2071283345 hasConceptScore W2071283345C2777722626 @default.
• W2071283345 hasConceptScore W2071283345C31174226 @default.
• W2071283345 hasConceptScore W2071283345C42219234 @default.
• W2071283345 hasConceptScore W2071283345C44249647 @default.
• W2071283345 hasConceptScore W2071283345C50440223 @default.
• W2071283345 hasConceptScore W2071283345C71924100 @default.
• W2071283345 hasIssue "6" @default.
• W2071283345 hasLocation W20712833451 @default.
• W2071283345 hasLocation W20712833452 @default.
• W2071283345 hasOpenAccess W2071283345 @default.
• W2071283345 hasPrimaryLocation W20712833451 @default.
• W2071283345 hasRelatedWork W2052711060 @default.
• W2071283345 hasRelatedWork W2071283345 @default.
• W2071283345 hasRelatedWork W2127614605 @default.
• W2071283345 hasRelatedWork W2625136823 @default.
• W2071283345 hasRelatedWork W2902880117 @default.
• W2071283345 hasRelatedWork W2931429141 @default.
• W2071283345 hasRelatedWork W3136483994 @default.
• W2071283345 hasRelatedWork W4210912886 @default.
• W2071283345 hasRelatedWork W4220820621 @default.
• W2071283345 hasRelatedWork W2512502974 @default.
• W2071283345 hasVolume "130" @default.
• W2071283345 isParatext "false" @default.

• next